Skip to main content

Table 1 Patient characteristics of the mFAS2 population (MORA and NOCT combined)

From: 1L NER1006 can improve rates of adequate and high-quality bowel cleansing in the right colon: a post hoc analysis of two randomised clinical trials

Characteristic N2D (n = 517) N1D (n = 270) 2LPEG (n = 260) OSS (n = 260)
Sex, n (%)
 Female 280 (54.1) 145 (53.7) 123 (47.3) 115 (44.2)
 Male 237 (45.8) 125 (46.3) 137 (52.7) 145 (55.8)
Age group, n (%)
 ≤ 65 years 400 (77.4) 210 (77.8) 214 (82.3) 213 (81.9)
  > 65 years 117 (22.6) 60 (22.2) 46 (17.7) 47 (18.1)
Race, n (%)
 White/Caucasian 473 (91.5) 267 (98.9) 257 (98.8) 215 (82.7)
 Black 36 (7.0) 3 (1.1) 1 (0.4) 24 (9.2)
 Asian 7 (1.4) 0 2 (0.8) 16 (6.2)
 Other 6 (1.2) 0 0 5 (1.9)
BMI, n 514 268 256 260
 Mean (kg/m2) (SD) 28.4 (5.3) 26.9 (4.3) 26.4 (4.1) 29.7 (6.2)
 Patients with BMI > 25 kg/m2, n (%) 371 (72.2) 175 (65.3) 154 (60.2) 201 (77.3)
Colonoscopy indication, n (%)
 Screening 283 (54.7) 137 (50.7) 129 (49.6) 157 (60.4)
 Surveillance 141 (27.3) 57 (21.1) 60 (23.1) 76 (29.2)
 Diagnosis 93 (18.0) 76 (28.1) 71 (27.3) 27 (10.4)
Time lapse—preparation to colonoscopy, n 512 266 253 258
 Mean (SD) time (hours) between the last dose of bowel preparation and colonoscopy 5.6 (1.9) 5.4 (1.7) 5.4 (2.1) 5.3 (2.1)
  1. 2LPEG, 2L polyethylene glycol plus ascorbate; BMI, body mass index; mFAS2, modified full analysis set 2; N1D, NER1006 same-day morning-only dosing regimen; N2D, NER1006 2-day evening/morning split-dosing regimen; OSS, oral sulphate solution; SD, standard deviation